Trial Profile
Gaucher Disease Registry Protocol
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 22 Apr 2024
Price :
$35
*
At a glance
- Drugs Alglucerase (Primary) ; Eliglustat (Primary) ; Imiglucerase (Primary)
- Indications Gaucher's disease; Gaucher's disease type I
- Focus Therapeutic Use
- Sponsors Sanofi Genzyme
- 15 Jun 2023 Results (n=381) assessing the hematologic and visceral response to eliglustat in patients enrolled in the ICGG GaucherRegistry across long-term follow-up presented at the 28th Congress of the European Haematology Association
- 02 Feb 2022 Results (N=32), of a subgroup analysis assessing the baseline characteristics of patients with Gaucher disease who were treated with Imiglucerase in South African group, published in the South African Medical Journal
- 15 Jul 2020 Protocol amended to include eliglustat drug and Gaucher Pregnancy Sub-registry in the trial.